Modern Medicine News

Vascular anomalies require team approachPatients with vascular anomalies benefit from multidisciplinary treatment often involving propranolol and/or sirolimus.
Sirolimus may reduce refractory hemangiomasmTOR inhibitor helps child with diffuse vascular anomalies and extensive organ involvement.
5 great books for holiday ‘you time’The holidays offer some time to unwind and recalibrate before the calendar flips to the new year. If you enjoy reading, here are five recommendations we hope will resonate with you, inspire you, and maybe move you into the New Year with just a little more insight and enthusiasm.
PRK enhancement after SMILE favorable after short follow-upSurface ablation performed with mitomycin-C (MMC) seems to be a safe and effective technique for treating residual refractive error after myopic SMILE, said Martin Dirisamer, MD.
Complicated cataracts pose almost no limits for adding MIGSComorbidity of glaucoma poses some increased risks for cataract surgery, but even when there are intraoperative complications during the lens removal procedure, it is almost always possible to still add micro-invasive glaucoma surgery (MIGS), said Reay H. Brown, MD.
Study explores ranibizumab as treatment for ROPIntravitreal ranibizumab (Lucentis, Genentech) appears to be effective for treatment of severe retinopathy of prematurity (ROP) and associated with less persistent suppression of systemic VEGF compared with bevacizumab (Avastin, Genentech), according to research reported by Shunji Kusaka, MD.
How yoga changed one OD’s life
How yoga changed one OD’s lifeNot many of us would rate the 6 a.m. breakfast hour CE at an optometric conference as a favorite or must-do experience. But you haven't been to a class by Danielle Richardson, OD.
Melanoma research roundupIn this slideshow, we highlight recently published research findings on newly identified genetic mutations associated with conjunctival melanoma, expanding the definition of melanoma to include population diversities, and dermatomyositis that fails treatment.
This is why we need to accelerate value-based care
This is why we need to accelerate value-based careMuch like the Accountable Care Act (ACA) debate in 2010, the current political debate over repealing and replacing the ACA is focused on coverage and cost.
Subretinal therapy offers promise of lighter treatment burden for AMDRGX-314 gene therapy offers patients the potential for a lower treatment burden with one subretinal injection of a gene therapy delivering an anti-vascular endothelial growth factor protein.